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บทคดัยอ่ 
วตัถุประสงค:์ ยาปฏชิวีนะมขีอ้จาํกดัในการนํามาใชก้บัรา่งกาย ซึง่ขอ้เสยี ไดแ้ก่ 
การเกดิอาการไมพ่งึประสงคจ์ากการใชย้า การแพย้า และทาํใหเ้ชือ้แบคทเีรยีบาง
ชนิดเกดิการดือ้ยา ดว้ยเหตุน้ีจงึมกีารศกึษาความเป็นไปไดใ้นการใชย้าปฏชิวีนะ
หลายชนิดรว่มกนัเพือ่ใหเ้กดิการเสรมิฤทธิข์องยาซึง่จะทาํใหส้ามารถเพิม่ฤทธิต์า้น
จลุชพี ลดความเป็นพษิ และลดความเสีย่งในการเกดิเชือ้ดือ้ยาลง วตัถุประสงคข์อง
การศกึษาน้ีคอืการทดสอบวา่ยาคูผ่สมระหวา่งดอ็กซไีซคลนิไฮเคลต, ซโิปรฟลอ็ก
ซาซนิ ไฮโดรคลอไรด,์ เมโทรนิดาโซล สามารถออกฤทธิเ์สรมิกนัเพือ่ยบัยัง้เชือ้
ชนิดต่างๆไดห้รอืไม ่ วธิกีารศกึษา: ศกึษาฤทธิต์า้นจลุชพีของยาดอ็กซไีซคลนิไฮ
เคลต, ซโิปรฟลอ็กซาซนิ ไฮโดรคลอไรด,์ เมโทรนิดาโซล และคูผ่สมของยาเหล่าน้ี
ต่อเชือ้แบคทเีรยีชนิดตอ้งการออกซเิจน ไดแ้ก่ Staphylococcus aureus กบั 
Escherichia coli และต่อเชือ้แบคทเีรยีชนิดทีไ่มต่อ้งการออกซเิจน ไดแ้ก่ 
Streptococcus mutans และ Porphyromonas gingivalis ผลการศกึษา: ผลของ
การศกึษาพบวา่ยาคู่ผสมระหวา่งดอ็กซไีซคลนิไฮเคลตกบัเมโทรนิดาโซลแสดงผล
ยบัยัง้เชือ้แบบเสรมิฤทธิต่์อเชือ้แบคทเีรยี Porphyromonas gingivalis โดยมคีา่ 
fractional inhibitory concentration (FICI) เทา่กบั 0.4 สรปุ: ยาคูผ่สมระหวา่งดอ็ก
ซไีซคลนิไฮเคลตกบัเมโทรนิดาโซสามารถแสดงผลยบัยัง้เชือ้แบบเสรมิฤทธิต่์อเชือ้
แบคทเีรยี Porphyromonas gingivalis การเสรมิฤทธิข์องยาคูผ่สมน้ีอาจมี
ประโยชน์สาํหรบัการรกัษาโรคปรทินัตอ์กัเสบ 
คาํสาํคญั: ดอ็กซไีซคลนิ, เมโทรนิดาโซล, พอรไ์ฟโรโมแนส จงิจวิาลสิ, การเสรมิ
ฤทธิข์องยาปฏชิวีนะ 
 
Abstract 
Objective: Administration of antibiotics is not without limitations. Certain 
drawbacks include adverse drug reactions, drug allergies and the emergence 
of antibiotic-resistant bacteria. To this end, antibiotic combinations with 
synergistic antimicrobial effects are sought after to establish combinations 
which exhibit an increased antimicrobial activity, decreased toxicity and 
lowered chance of antibiotic resistance development. This study aimed to 
test a synergistic antibacterial activity against selected pathogens of the 
combination of selected drugs, i.e. doxycycline hyclate, ciprofloxacin 
hydrochloride and metronidazole. Methods: Antibacterial activity of 
doxycycline hyclate, ciprofloxacin hydrochloride, metronidazole and their 
combinations against aerobic microbes (Staphylococcus aureus and 
Escherichia coli) and anaerobic microbes (Streptococcus mutans and 
Porphyromonas gingivalis) were evaluated using checkerboard method. 
Results: Our result indicated that doxycycline hyclate-metronidazole 
combination exhibited synergistic antimicrobial activity (fractional inhibitory 
concentration; FICI = 0.4) against the anaerobic pathogen Porphyromonas 
gingivalis. Conclusion: Doxycycline hyclate-metronidazole combination 
exhibited synergistic antimicrobial activity Porphyromonas gingivalis. This 
synergistic activity may be exploited in the management of periodontitis. 
Keywords: doxycycline, metronidazole, Porphyromonas gingivalis, antibiotics 
synergy  
Introduction 
Infectious diseases are serious health concerns caused 
by an invasion of microorganisms into the human body. A 
considerable proportion of infectious diseases are caused by 
bacteria. The severity of bacterial infections ranges from mild, 
topical infections to life-threatening, systemic infections 
involving multiple vital organs. Multiple classes of antibiotics 
have been developed and effectively used in the combat 
against these pathogens. However, the increased usage of 
antimicrobial agents has evoked the emergence of drug-
resistant microbes including methicillin-resistant Staphylo-
coccus aureus (MRSA), vancomycin-resistant enterococci 
(VRE), multidrug-resistant (MDR)-Pseudomonas aeruginosa, 
extended spectrum beta-lactamase (ESBLs)-producing 
Enterobacteriaceae and MDR-Acinetobacter baumannii1-3, 
which are considered to be emerging global crises associated 
with refractory response, increased mortality and higher cost 
of therapy. This has led to the development of antimicrobial 
combinations with a goal to seek combinations which exhibit 
synergistic effects to increase antimicrobial activity while also 
decreasing toxicity and the chance of bacteria to develop 
resistance.  
To assess the synergistic effects of antibacterial agents, 
three model drugs with diverse mechanisms of action were 
selected and evaluated against four microbes with different 
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molecular and metabolic backgrounds. Doxycycline is a 
broad-spectrum antibiotic in the class of tetracycline. It 
possesses a bacteriostatic activity through the inhibition of 
protein synthesis by preventing the binding of aminoacyl-tRNA 
to 30S ribosome4 and, at a subantimicrobial dose, inhibits 
matrix metalloproteinases (MMPs).5,6 The antibacterial activity 
of doxycycline is documented against a wide range of bacterial 
pathogens including Staphylococcus aureus7, Escherichia 
coli8, and Porphyromonas gingivalis9, while the sensitivity of 
Streptococcus mutans to tetracycline has been 
demonstrated.10,11  Ciprofloxacin is a member of 
fluoroquinolone antibiotics which inhibit DNA gyrase and 
topoisomerase IV resulting in the blockade of DNA 
synthesis.12,13 The antibacterial activity of ciprofloxacin against 
Staphylococcus aureus14, Escherichia coli15,16 and 
Porphyromonas gingivalis17 has been reported. Metronidazole 
is a nitroimidazole antimicrobial agent that inhibits DNA 
replication of anaerobic bacteria.18-20  The transformation of 
metronidazole to its active, reduced form is favored in an 
anaerobic condition.19,20 The reduced metronidazole triggers 
DNA strand breakage.19,20 Metronidazole is routinely 
prescribed for the management of anaerobic bacterial 
infection. Antibacterial activity of metronidazole against the 
anaerobes Streptococcus mutans21 and Porphyromonas 
gingivalis9,17 has been demonstrated.  
Four possible outcomes are expected from antimicrobial 
combinations.22 The interaction is classified as synergistic 
when the effect of the combined drugs is greater than the sum 
of each agent used individually. Additivity is when the drug 
combination possesses the antimicrobial activity equal to the 
sum of the activity of each drug used separately. Indifference 
is the relationship where the activity of the combination is 
equal to the activity of one of the two agents used individually. 
Lastly, antagonism is a phenomenon when the combination is 
less effective than each agent used individually. A strategy 
which may be employed to study the activity of antimicrobial 
combinations is the checkerboard test.22-24  
To assess the synergistic effect of antibacterial agents, 
the antibacterial activity of doxycycline hyclate, ciprofloxacin 
hydrochloride, metronidazole and their combinations against 
aerobic microbes (Staphylococcus aureus ATCC 6853P and 
Escherichia coli ATCC 25922) and anaerobic microbes 
(Streptococcus mutans ATCC 27175 and Porphyromonas 
gingivalis ATCC 33277) were evaluated using the 
checkerboard method while the standard fungal pathogen 
Candida albicans ATCC 17110 was used as negative control.  
 
Materials and Methods 
 
 
Microbial strains and antimicrobial agents 
Doxycycline hyclate was purchased from Huashu 
pharmaceutical corporation, Shijiazhuang, China (Batch No. 
20071121). Ciprofloxacin hydrochloride and metronidazole 
were kindly supplied by T. MAN Pharma Ltd, Bangkok, 
Thailand. Standard microbes included Staphylococcus aureus 
ATCC 6538P, Escherichia coli ATCC 25922, Candida albicans 
ATCC 17110, Streptococcus mutans ATCC 27175 and 
Porphyromonas gingivalis ATCC 33277. 
 
Bacterial culture  
Each microbe was cultured in appropriate media. Tryptic 
soy broth (lot no. 8091999, DifcoTM, USA) was used for S. 
aureus and E.coli. Sabouraud dextrose broth (lot no. 6345690, 
DifcoTM, USA) was used for C. albicans. Brain heart infusion 
broth (lot no. 0270845, BactoTM, USA) was used for S. mutans 
and P. gingivalis. Microbes were incubated in an aerobic 
incubator (for aerobic microbes S. aureus, E.coli and C. 
albicans) or anaerobic incubator (Forma Anaerobic System, 
Thermo Scientific, Ohio, USA, for anaerobic microbes S. 
mutans and P. gingivalis) at 37 °C, for 24 - 48 h. The 
relationship between the number of microbes and optical 
density at 530 or 540 nm was determined using a UV-vis 
spectrophotometer (Perkin-Elmer, Germany) (n = 3). The 
suspension was further diluted to obtain a final inoculum 
density of 2x105 cfu/mL.  
 
Minimal inhibitory concentration (MIC) determination  
MICs of each antimicrobial agent against standard 
microbes were determined by broth microdilution method. MIC 
was defined as the lowest concentration of antimicrobial 
agents which inhibited the growth of the tested microbe (n = 
6).  
 
Assessment of antimicrobial combination by 
checkerboard test  
Checkerboard test was performed in microtiter plates (96 
well plates, U-bottom with lid, Corning Incorporated, USA). 
Antimicrobial activity of the drug combinations was determined 
by microdilution method. Antimicrobial agents were prepared 
at 1.25, 6.4, 4.0 and 12.8 mg/mL, respectively. Fifty μL of 
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diluted microbial agents were distributed to each well.  Then, 
200 μL of 1x105 cfu/mL microbial suspension were added to 
each well and incubated at 37 °C for 24 h. The antimicrobial 
efficacy of each drug in the combination treatment was 
expressed in terms of fractional inhibitory concentration (FIC), 
which is defined as the MIC of the drug used in combination 
divided by the MIC of the drug used alone. Finally the FIC of 
each drug in the combination was used to calculate the 
fractional inhibitory concentration index (FICI) using the 
following formula:  
FICI = FICA + FICB  
where FICA and FICB are FIC of drug A and B, respectively. 
FICI < 0.5 signified a synergistic antimicrobial effect of the 
drug combination, 0.5  FICI < 1.0 was interpreted as additive, 
1  FICI < 4.0 was interpreted as indifference and FICI > 4 
was interpreted as antagonistic.22-24  
 
Results 
 
 
The efficacy of doxycycline hyclate, ciprofloxacin 
hydrochloride, metronidazole and their combinations against 
aerobic microbes (S. aureus, E. coli and C. albicans) and 
anaerobic microbes (S. mutans and P. gingivalis) were 
evaluated by MICs and FIC index. To establish reference 
efficacies of each individual antimicrobial agent, the MICs of 
doxycycline hyclate, ciprofloxacin hydrochloride and 
metronidazole against S. aureus, E. coli, C. albicans, S. 
mutans and P. gingivalis were determined by broth 
microdilution method (Table 1). The standard curves for each 
microbe were presented in Figure 1. The good relationship 
was evident by R2 in the range of 0.9950 - 0.9979.  
Next, the effects of antimicrobial combinations were 
evaluated by the checkerboard method. The FICI of each 
combination was shown in Table 2. As expected, all 
antibacterial combinations demonstrated an indifferent effect 
against the fungus C. albicans which was used as a negative 
control. Doxycycline hyclate-ciprofloxacin HCl combination 
exhibited an indifferent relationship against all aerobic 
microbes (S. aureus, and E. coli) and against S. mutans while 
exhibiting an additive effect against P. gingivalis (Table 2). 
Doxycycline hyclate-metronidazole and ciprofloxacin HCl-
metronidazole combinations exhibited additive effects against 
S. aureus and S. mutans but demonstrated indifferent 
relationship against E. coli. Ciprofloxacin HCl-metronidazole 
combination showed an indifferent effect against P. gingivalis. 
Interestingly, doxycycline hyclate-metronidazole combination 
demonstrated a synergistic effect against the anaerobic 
pathogen P. gingivalis (Table 2). Further research into this 
synergism is warranted to assess its usefulness in the combat 
against P. gingivalis infections such as in periodontitis.   
   
 Table 1  Minimal inhibitory concentrations (MICs) of 
antimicrobial agents against S. aureus ATCC 6538P, E. coli 
ATCC 25922, C. albicans ATCC 17110,  S. mutans ATCC 27175 
and P. gingivalis ATCC 33277 determined by broth microdilution 
method (n = 3).    
MIC  
(μg/mL) 
Drugs 
Doxycycline  
hyclate 
Ciprofloxacin Metronidazole 
S. aureus 0.08+0.00 0.25+0.02 1.60+0.05 
E. coli 0.20+0.01 0.27+0.03 5.69+0.05 
C. albicans 2.50+0.04 1.06+0.02 11.38+0.06 
S. mutans 0.21+0.01 0.97+0.00 3.20+0.21 
P. gingivalis 1.88+0.04 0.31+0.01 0.80+0.02 
   
 
     
 
 
Figure 1  (A) Calibration curve of Staphylococcus aureus ATCC 
6853P, (B) Escherichia coli ATCC 25922, (C) Candida albicans 
ATCC 17110, (D) Streptococcus mutans ATCC 27175 and (E) 
Porphyromonas gingivalis ATCC 33277   
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 Table 2  Fractional inhibitory concentration (FIC) index 
values of the drug combinations.  
Combined 
drugs 
FIC in the combination 
FICI Interpretation 
FICA FICB 
S. aureus     
D + C 0.67 0.40 1.07 ID 
D + M 0.40 0.40 0.80 AD 
C + M 0.50 0.33 0.83 AD 
E. coli     
D + C 0.40 0.75 1.15 ID 
D + M 0.50 0.83 1.33 ID 
C + M 1.00 0.25 1.25 ID 
C. albicans     
D + C 1.00 0.25 1.25 ID 
D + M 1.00 0.20 1.20 ID 
C + M 0.83 0.20 1.03 ID 
S. mutans     
D + C 0.50 0.63 1.13 ID 
D + M 0.30 0.20 0.50 AD 
C + M 0.10 0.75 0.85 AD 
P. gingivalis     
D + C 0.10 0.40 0.50 AD 
D + M 0.10 0.30 0.40 S 
C + M 0.30 0.75 1.05 ID 
Note: D: Doxycycline hyclate; C: Ciprofloxacin; M: Metronidazole; S: Synergy; AD: Additive; ID: 
Indifference.   
 
Discussions and Conclusion 
 
Due to the limited number of antibiotics available and the 
emergence of antibiotic resistance at alarming rate, novel 
antibiotics as well as innovative strategies to use them against 
infections are areas of active research. Given the challenges 
in the discovery of novel antibiotics, synergy between 
antibacterial agents has been proposed as an alternative 
strategy for the management of infection. Extensive 
researches in this area have extended the synergism beyond 
those routinely prescribed antibiotics to include the synergy 
between existing antibiotics and plant-derived compounds and 
other non-traditional antibacterial agents.25 However, an 
intrinsic limitation of antibiotic combination studies is that it 
requires tremendous effort to study all possible combinations 
of antibiotics against pathogens of interest, not to mention the 
genetic variability of bacteria even within species which adds 
yet another layer of complication and possibly accountable for 
the discrepancies in experimental results between research 
groups. Nevertheless, our results provide a proof-of-concept 
that antibiotic combination may be beneficial in the combat 
against bacterial pathogens, at least in the case of doxycycline 
hyclate and metronidazole combination against P. gingivalis.  
Despite the fact that the mechanisms of antibacterial 
synergism are likely case-specific, the interaction of antibiotics 
in a combination can be classified into three main categories: 
(1) drugs which target different pathways within bacteria, (2) 
drugs that inhibit different targets in the same pathways and 
(3) drugs which target the same molecules in different 
ways.25,26 Unanticipated antibacterial effects of antibiotics 
normally ineffective against tested pathogens have been 
reported when used in combination with other compounds. 
The mechanisms of such events are largely explained by the 
ability of the added compound in the sensitization of the 
pathogen to the antibiotics by, but not limited to, two main 
mechanisms: one involves an inhibition of enzymes which 
target the antibiotics for destruction such as the restoration of 
the effectiveness of beta-lactam antibiotics against MRSA in 
the presence of epigallocatechin gallate which inhibits 
bacterial beta-lactamase enzyme, and the other involves an 
increase in the intracellular concentration of antibiotics by the 
modulation of bacterial barriers or pumps such as the 
sensitization of MRSA to tetracycline by reserpine and the 
restored effectiveness of ciprofloxacin against gram positive 
and gram negative bacteria by epigallocatechin gallate.25 
Moreover, it may be important to mention that antibacterial 
synergy can also result from compounds that have no 
antimicrobial activity against the organism by themselves, but 
can sensitize the organism to antibiotics, as is the case for 
beta-lactamase inhibitors and beta-lactam antibiotics.27  
Despite the attractive benefits of antibiotic combinations, 
case-by-case considerations must be made in order to 
speculate clinical performances. Many factors affect the 
interpretation of in vitro antibiotic interaction, including but not 
limited to (1) test methods, i.e. checkerboard microdilution, 
time-kill method and Etest, (2) outcomes, i.e. inhibition or 
killing, and (3) experimental setting, e.g. concentration of 
bacteria, treatment time, etc, as exemplified by the interaction 
between polymixins and carbapenem.28 Moreover, 
pharmacokinetic factors, site of infection and time frame 
governed by treatment regimen can be anticipated to 
complicate the extrapolation of in vitro data to predict clinical 
outcomes.  
Periodontitis is the inflammation of the periodontium 
caused by the accumulation of bacteria in the periodontal 
pocket.29 Common pathogens causing periodontitis include 
Porphyromonas gingivalis, Actinobacillus actinomycetem-
comitans, Fusobacterium nucleatum, Bacteroides forsythus 
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and Treponema denticola.30,31 Other gram negative anaerobic 
rods, certain gram positive bacteria and enteric rods/ 
pseudomonas may also play roles in the pathogenesis of 
periodontitis.30,31 According to the clinical practice guideline 
issued by the American Dental Association, scaling and root 
planning (SRP) is the standard intervention for the 
management of chronic periodontitis.9 Additionally, systemic 
subantimicrobial-dose of doxycycline (20 milligrams twice a 
day for 3 to 9 months) and systemic antimicrobials (amoxicillin 
and metronidazole, metronidazole, azithromycin, clarithro-
mycin, moxifloxacin, and tetracyclines including doxycycline at 
an antimicrobial dose of 100 milligrams or greater per day) 
may be considered as adjunct therapies to SRP.9 However, 
systemic antibiotics only provide little benefit, i.e. a small gain 
in tooth attachment9, while also potentially giving rise to 
adverse reactions commonly associated with antibiotics such 
as rash, diarrhea, abdominal pain, nausea, vomiting and rare 
but life-threatening events i.e. the diverse types of allergic 
reactions. These limitations highlight the need for the 
development of new antimicrobial agents or new therapeutic 
strategies which are more effective and safer for the treatment 
of periodontitis.  
A strategy which may be used to devise a more effective 
pharmacological intervention is to exploit the synergism 
between antimicrobial agents. Synergism is the phenomenon 
when two antimicrobial agents with complementary 
mechanisms of action are used against a pathogen the effect 
of the drug combination is greater than the sum of each 
individual agent used separately.22,24,32 Synergism allows the 
usage of each agent at lower doses which provides a benefit 
in decreasing the adverse effects associated with the 
concentration of each molecule.22,24,32 Our results 
demonstrated a synergistic relationship between doxycycline 
hyclate and metronidazole against P. gingivalis, a common 
pathogen causing periodontitis, suggesting that the 
combination may be useful for periodontitis treatment. 
Previously, the efficacy of metronidazole and doxycycline in 
the prevention of recurrent periodontitis was investigated by 
Atiken et al.33 Briefly, patients suffering periodontitis were 
treated with bimonthly scaling and 3 weeks of systemic 
doxycycline (11 subjects) or scaling and placebo (12 
subjects).33 Patients were then monitored for signs of 
recurrent periodontitis, i.e. a present of periodontal abscess or 
loss of gingival attachment. Upon the detection of recurrent 
periodontitis, metronidazole was administered (250 mg every 
8 hours) for 10 days. The investigators reported a 42% 
recurrent periodontitis in placebo group compared to 9% in 
doxycycline group, as well as a marked reduction in 
periodontitis pathogens Actinobacillus actinomycetemcom-
itans, Porphyromonas gingivalis, Prevotella intermedia, 
Eikenella corrodens, and Fusobacterium nucleatum before 
and one month after metronidazole administration in 
doxycycline group compared to placebo, suggesting that pre-
exposure to doxycycline sensitized periodontitis pathogens to 
metronidazole.33  
The mechanism of doxycycline and metro-nidazole 
synergy remains largely inconclusive. However, it will be 
interesting to investigate if the synergism is a specific effect of 
doxycycline and metronidazole or if the synergy is extended 
to other agents of the same class. A class effect would 
indicate that the synergism is attributable to the combinatorial 
inhibition of protein synthesis and DNA replication by 
tetracycline and nitroimidazole antibiotics, respectively; while 
a molecule-specific effect would suggest that the synergism 
results from certain molecular structure unique to doxycycline 
and/or metronidazole. Additionally, it may be worthwhile to 
examine the intracellular concentration of doxycycline and 
metronidazole when used individually and in combination, as 
changes in the intracellular concentration will suggest that the 
synergism may result from the ability of an agent to interfere 
with the drug export/import mechanism of the bacteria. Further 
research into this synergism is warranted to assess its 
usefulness in the management of periodontitis. Moreover, the 
efficacy of certain antimicrobial combinations is greater when 
sequentially administered as compared to a concomitant 
treatment.34 The efficacy of doxycycline hyclate and 
metronidazole combination, both concomitantly and 
sequentially administered, against P. gingivalis and other 
periodontitis pathogens awaits further evaluation.  
 
Conclusion  
Using checkerboard method, antibacterial activity of 
doxycycline hyclate, ciprofloxacin hydrochloride, metro-
nidazole and their combinations were evaluated against 
aerobic microbes (Staphylococcus aureus and Escherichia 
coli) and anaerobic microbes (Streptococcus mutans and 
Porphyromonas gingivalis). Our result indicated that the 
combination of doxycycline hyclate and metronidazole 
exhibited synergy (fractional inhibitory concentration; FICI = 
0.4) against the anaerobic pathogen Porphyromonas 
ไทยเภสชัศาสตรแ์ละวทิยาการสขุภาพ ปี 11 ฉบับ 3, กค. – กย. 2559 97 Thai Pharm Health Sci J Vol. 11 No. 3, Jul. – Sep. 2016 
gingivalis, a common pathogen causing periodontitis, 
suggesting that the combination may be useful for the 
management of periodontal disease.  
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